Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
Market Analysis and Insights: Global Duchenne Muscular Dystrophy Therapeutics Market
In 2019, the global Duchenne Muscular Dystrophy Therapeutics market size was US$ 961.9 million and it is expected to reach US$ 5792.4 million by the end of 2026, with a CAGR of 28.9% during 2021-2026.
Global Duchenne Muscular Dystrophy Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Duchenne Muscular Dystrophy Therapeutics market is segmented into Pain Management Drugs, Corticosteroids, Prednisolone, Prednisone, Deflazacort, etc.
Segment by Application, the Duchenne Muscular Dystrophy Therapeutics market is segmented into Hospitals, Clinics, Home Care Settings, etc.
Regional and Country-level Analysis
The Duchenne Muscular Dystrophy Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Duchenne Muscular Dystrophy Therapeutics market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.
Competitive Landscape and Duchenne Muscular Dystrophy Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy Therapeutics market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Duchenne Muscular Dystrophy Therapeutics business, the date to enter into the Duchenne Muscular Dystrophy Therapeutics market, Duchenne Muscular Dystrophy Therapeutics product introduction, recent developments, etc.
The major vendors include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US), Santhera Pharmaceuticals (Switzerland), Sarepta Therapeutics (US), etc.
This report focuses on the global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Duchenne Muscular Dystrophy Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Market segment by Type, the product can be split into
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Market segment by Application, split into
Hospitals
Clinics
Home Care Settings
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Duchenne Muscular Dystrophy Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Therapeutics are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
Market Analysis and Insights: Global Duchenne Muscular Dystrophy Therapeutics Market
In 2019, the global Duchenne Muscular Dystrophy Therapeutics market size was US$ 961.9 million and it is expected to reach US$ 5792.4 million by the end of 2026, with a CAGR of 28.9% during 2021-2026.
Global Duchenne Muscular Dystrophy Therapeutics Scope and Market Size
Duchenne Muscular Dystrophy Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Duchenne Muscular Dystrophy Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Segment by Type, the Duchenne Muscular Dystrophy Therapeutics market is segmented into Pain Management Drugs, Corticosteroids, Prednisolone, Prednisone, Deflazacort, etc.
Segment by Application, the Duchenne Muscular Dystrophy Therapeutics market is segmented into Hospitals, Clinics, Home Care Settings, etc.
Regional and Country-level Analysis
The Duchenne Muscular Dystrophy Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Duchenne Muscular Dystrophy Therapeutics market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.
Competitive Landscape and Duchenne Muscular Dystrophy Therapeutics Market Share Analysis
Duchenne Muscular Dystrophy Therapeutics market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Duchenne Muscular Dystrophy Therapeutics business, the date to enter into the Duchenne Muscular Dystrophy Therapeutics market, Duchenne Muscular Dystrophy Therapeutics product introduction, recent developments, etc.
The major vendors include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US), Santhera Pharmaceuticals (Switzerland), Sarepta Therapeutics (US), etc.
This report focuses on the global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Duchenne Muscular Dystrophy Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
Bristol-Myers Squibb
FibroGen (US)
Italfarmaco (Italy)
Marathon
NS Pharma (US)
PTC Therapeutics (US)
Pfizer
ReveraGen BioPharma (US)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (US)
Market segment by Type, the product can be split into
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Market segment by Application, split into
Hospitals
Clinics
Home Care Settings
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Duchenne Muscular Dystrophy Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.
In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Therapeutics are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Therapeutics Revenue
1.4 Market Analysis by Type
1.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Pain Management Drugs
1.4.3 Corticosteroids
1.4.4 Prednisolone
1.4.5 Prednisone
1.4.6 Deflazacort
1.5 Market by Application
1.5.1 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Home Care Settings
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends by Regions
2.1 Duchenne Muscular Dystrophy Therapeutics Market Perspective (2015-2026)
2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Regions
2.2.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Duchenne Muscular Dystrophy Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Duchenne Muscular Dystrophy Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Duchenne Muscular Dystrophy Therapeutics Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Market Size
3.1.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio
3.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Therapeutics Revenue in 2019
3.3 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
3.4 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
3.5 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2015-2026)
4.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2021-2026)
5 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Application (2015-2026)
5.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
6.2 Duchenne Muscular Dystrophy Therapeutics Key Players in North America (2019-2020)
6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
6.4 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
7.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
7.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
8 China
8.1 China Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
8.2 Duchenne Muscular Dystrophy Therapeutics Key Players in China (2019-2020)
8.3 China Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
8.4 China Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
9 Japan
9.1 Japan Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
9.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
9.4 Japan Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
10.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
11 India
11.1 India Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
11.2 Duchenne Muscular Dystrophy Therapeutics Key Players in India (2019-2020)
11.3 India Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
11.4 India Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size (2015-2020)
12.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Bristol-Myers Squibb
13.1.1 Bristol-Myers Squibb Company Details
13.1.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Introduction
13.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020))
13.1.5 Bristol-Myers Squibb Recent Development
13.2 FibroGen (US)
13.2.1 FibroGen (US) Company Details
13.2.2 FibroGen (US) Business Overview and Its Total Revenue
13.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Introduction
13.2.4 FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.2.5 FibroGen (US) Recent Development
13.3 Italfarmaco (Italy)
13.3.1 Italfarmaco (Italy) Company Details
13.3.2 Italfarmaco (Italy) Business Overview and Its Total Revenue
13.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Introduction
13.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.3.5 Italfarmaco (Italy) Recent Development
13.4 Marathon
13.4.1 Marathon Company Details
13.4.2 Marathon Business Overview and Its Total Revenue
13.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Introduction
13.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.4.5 Marathon Recent Development
13.5 NS Pharma (US)
13.5.1 NS Pharma (US) Company Details
13.5.2 NS Pharma (US) Business Overview and Its Total Revenue
13.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
13.5.4 NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.5.5 NS Pharma (US) Recent Development
13.6 PTC Therapeutics (US)
13.6.1 PTC Therapeutics (US) Company Details
13.6.2 PTC Therapeutics (US) Business Overview and Its Total Revenue
13.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
13.6.4 PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.6.5 PTC Therapeutics (US) Recent Development
13.7 Pfizer
13.7.1 Pfizer Company Details
13.7.2 Pfizer Business Overview and Its Total Revenue
13.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Introduction
13.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.7.5 Pfizer Recent Development
13.8 ReveraGen BioPharma (US)
13.8.1 ReveraGen BioPharma (US) Company Details
13.8.2 ReveraGen BioPharma (US) Business Overview and Its Total Revenue
13.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
13.8.4 ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.8.5 ReveraGen BioPharma (US) Recent Development
13.9 Santhera Pharmaceuticals (Switzerland)
13.9.1 Santhera Pharmaceuticals (Switzerland) Company Details
13.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview and Its Total Revenue
13.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Introduction
13.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
13.10 Sarepta Therapeutics (US)
13.10.1 Sarepta Therapeutics (US) Company Details
13.10.2 Sarepta Therapeutics (US) Business Overview and Its Total Revenue
13.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
13.10.4 Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2015-2020)
13.10.5 Sarepta Therapeutics (US) Recent Development
14 Analyst's Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
